Candel Therapeutics (CADL) Non Operating Income (2020 - 2025)
Candel Therapeutics recorded quarterly Non Operating Income of -$23.7 million in Q4 2025, down 1324.92% quarter-over-quarter from $1.9 million in Q3 2025, and down 300.19% year-over-year from $11.9 million in Q4 2024.
Candel Therapeutics' Non Operating Income history runs 6 years deep, the most recent figure standing at -$23.7 million for Q4 2025.
- In Q4 2025, Non Operating Income fell 300.19% year-over-year to -$23.7 million; the TTM figure through Dec 2025 stood at $89000.0 (up 100.41% YoY), while the FY2025 annual figure was $89000.0, up 100.41% from the prior year.
- Non Operating Income came in at -$23.7 million for Q4 2025 at Candel Therapeutics, down from $1.9 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $15.5 million in Q1 2025 to a low of -$23.7 million in Q4 2025.
- A 5-year average of -$414850.0 and a median of $155000.0 in 2021 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income jumped 6521.28% in 2021 and slumped 38945.71% in 2024, its largest moves.
- Candel Therapeutics' Non Operating Income stood at $9.3 million in 2021, then sank by 67.67% to $3.0 million in 2022, then slumped by 125.75% to -$777000.0 in 2023, then plunged by 663.45% to -$5.9 million in 2024, then sank by 300.19% to -$23.7 million in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered -$23.7 million, $1.9 million, and $6.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | -23.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23.74 Mn |
| Sep 30, 2025 | 1.94 Mn |
| Jun 30, 2025 | 6.38 Mn |
| Mar 31, 2025 | 15.51 Mn |
| Dec 31, 2024 | -5.93 Mn |
| Sep 30, 2024 | -1.89 Mn |
| Jun 30, 2024 | -13.67 Mn |
| Mar 31, 2024 | -319,000.00 |
| Dec 31, 2023 | -777,000.00 |
| Sep 30, 2023 | 426,000.00 |
| Jun 30, 2023 | -35,000.00 |
| Mar 31, 2023 | 12,000.00 |
| Dec 31, 2022 | 3.02 Mn |
| Sep 30, 2022 | 193,000.00 |
| Jun 30, 2022 | 4.60 Mn |
| Mar 31, 2022 | 8.11 Mn |
| Dec 31, 2021 | 9.34 Mn |
| Sep 30, 2021 | 131,000.00 |
| Jun 30, 2021 | -11.78 Mn |
| Mar 31, 2021 | 179,000.00 |
| Dec 31, 2020 | 141,000.00 |
| Sep 30, 2020 | 154,000.00 |
| Jun 30, 2020 | -257,000.00 |